Cellect Biotechnology Ltd. (APOP) Analysts See $-0.30 EPS as of June, 4

May 17, 2018 - By Darrell Taylor

Cellect Biotechnology Ltd. (NASDAQ:APOP) is awaited to report earnings on June, 4., RTT reports. Analysts forecast $-0.30 earnings per share, which is $0.26 down or 650.00 % from 2017’s $-0.04 earnings per share. 87.50 % negative EPS growth is what Wall Street’s sees after $-0.16 reported EPS previous quarter. Ticker’s shares touched $7.13 during the last trading session after 0.28% change.Currently Cellect Biotechnology Ltd. is downtrending after 42.02% change in last May 17, 2017. APOP has 17,074 shares volume. The stock underperformed the S&P500 by 53.57%.

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel.The company has $46.41 million market cap. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.Last it reported negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: